

References

- Adrián, M.-M., Rayo, M.-O., Licet, V.-T., Baines Simon, D., Adrián, C.-O., & Elvira, G.-G. (2020). Molecular epidemiology of predominant and emerging *Clostridioides difficile* ribotypes. *Journal of Microbiological Methods*, 105974.
- Allegretti, J. R., Kearney, S., Li, N., Bogart, E., Bullock, K., Gerber, G. K., ... & Korzenik, J. R. (2016). Recurrent *Clostridium difficile* infection associates with distinct bile acid and microbiome profiles. *Alimentary pharmacology & therapeutics*, 43(11), 1142-1153.
- Antonara, S., & Leber, A. L. (2016). Diagnosis of *Clostridium difficile* infections in children. *Journal of clinical microbiology*, 54(6), 1425-1433.
- Appiah, T., Boakye, Y. D., & Agyare, C. (2017). Antimicrobial Activities and Time-Kill Kinetics of Extracts of Selected Ghanaian Mushrooms. *Evidence-based complementary and alternative medicine: eCAM*, 2017
- Awad, M. M., Johanesen, P. A., Carter, G. P., Rose, E., & Lyras, D. (2014). *Clostridium difficile* virulence factors: insights into an anaerobic spore-forming pathogen. *Gut microbes*, 5(5), 579-593.
- Baines, S. D., & Wilcox, M. H. (2015). Antimicrobial resistance and reduced susceptibility in *Clostridium difficile*: potential consequences for induction, treatment, and recurrence of C. difficile infection. *Antibiotics*, 4(3), 267-298.
- Balouiri, M., Sadiki, M., & Ibsouda, S. K. (2016). Methods for in vitro evaluating antimicrobial activity: A review. *Journal of Pharmaceutical Analysis*, 6(2), 71–79.
- Banawas S. S. (2018). *Clostridium difficile* Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. *BioMed research international*, 2018, 1-9. 8414257.
- Bouchet, V., Huot, H., & Goldstein, R. (2008). Molecular genetic basis of ribotyping. *Clinical microbiology reviews*, 21(2), 262–273.
- Britton, R. A., & Young, V. B. (2012). Interaction between the intestinal microbiota and host in *Clostridium difficile* colonization resistance. *Trends in microbiology*, 20(7), 313–319.
- Buonomo, E. L., & Petri Jr, W. A. (2016). The microbiota and immune response during *Clostridium difficile* infection. *Anaerobe*, 41, 79-84.
- Center for Diseases Control and Prevention [CDC]. (2020). CDI Prevention Strategies
- Chai, C., Lee, K.-S., Lee, D., Lee, S., & Oh, S.-W. (2015). Non-selective and selective enrichment media for the recovery of *Clostridium difficile* from chopped beef. *Journal of Microbiological Methods*, 109, 20–24.
- Collins, D. A., & Riley, T. V. (2019). *Clostridium difficile* in Asia: opportunities for one health management. *Tropical medicine and infectious disease*, 4(1), 7.
- Czepiel, J., Pituch, H., Kuijper, E. J., Perucki, W., & Mielimonka, A. (2019). *Clostridium difficile* infection: review. *European Journal of Clinical Microbiology & Infectious Diseases*, 38(7), 1211-1221.
- Di Bella, S., Ascenzi, P., Siarakas, S., Petrosillo, N., & di Masi, A. (2016). *Clostridium difficile* toxins A and B: insights into pathogenic properties and extraintestinal effects. *Toxins*, 8(5), 134.

- Europe Center of Disease Control and Prevention [ECDC]. (2020). *Clostridium difficile* infections - Facts and surveillance.
- Edwards, A. N., Suárez, J. M., & McBride, S. M. (2013). Culturing and maintaining *Clostridium difficile* in an anaerobic environment. *JoVE (Journal of Visualized Experiments)*, (79), e50787.
- Eglow, R., Pothoulakis, C., Itzkowitz, S., Israel, E. J., O'Keane, C. J., Gong, D., Gao, N., Xu, Y. L., Walker, W. A., & LaMont, J. T. (1992). Diminished *Clostridium difficile* toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. *The Journal of clinical investigation*, 90(3), 822–829.
- Evans, C. T., & Safdar, N. (2015). Current trends in the epidemiology and outcomes of *Clostridium difficile* infection. *Clinical Infectious Diseases*, 60(suppl_2), S66-S71.
- Francino M. P. (2016). Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. *Frontiers in microbiology*, 6, 1543.
- Goudarzi, M., Seyedjavadi, S. S., Goudarzi, H., Mehdizadeh Aghdam, E., & Nazeri, S. (2014). *Clostridium difficile* infection: epidemiology, pathogenesis, risk factors, and therapeutic options. *Scientifica*, 2014, 1-9.
- Harnvoravongchai, P., Chankhamhaengdecha, S., Ounjai, P., Singhakaew, S., Boonthaworn, K., & Janvilisri, T. (2018). Antimicrobial Effect of Asiatic Acid Against *Clostridium difficile* Is Associated With Disruption of Membrane Permeability. *Frontiers in microbiology*, 9, 2125.
- Hookman, P., & Barkin, J. S. (2009). *Clostridium difficile* associated infection, diarrhea and colitis. *World journal of gastroenterology: WJG*, 15(13), 1554
- Indra, A., Blaschitz, M., Kernbichler, S., Reischl, U., Wewalka, G., & Allerberger, F. (2010). Mechanisms behind variation in the *Clostridium difficile* 16S–23S rRNA intergenic spacer region. *Journal of medical microbiology*, 59(Pt 11), 1317.
- Isidro, J., Menezes, J., Serrano, M., Borges, V., Paixão, P., Mimoso, M., ... & Oleastro, M. (2018). Genomic study of a *Clostridium difficile* multidrug resistant outbreak-related clone reveals novel determinants of resistance. *Frontiers in microbiology*, 9, 2994.
- Janezic, S. (2016). Direct PCR-Ribotyping of *Clostridium difficile*. In *Clostridium difficile* (pp. 15-21). Humana Press, New York, NY.
- Janoir, C. (2016). Virulence factors of *Clostridium difficile* and their role during infection. *Anaerobe*, 37, 13–24.
- Jarrad, A. M., Karoli, T., Blaskovich, M. A., Lyras, D., & Cooper, M. A. (2015). *Clostridium difficile* drug pipeline: challenges in discovery and development of new agents. *Journal of medicinal chemistry*, 58(13), 5164–5185.
- Jenkins, S. G., & Schuetz, A. N. (2012, March). Current concepts in laboratory testing to guide antimicrobial therapy. In *Mayo Clinic Proceedings* (Vol. 87, No. 3, pp. 290-308). Elsevier.
- Jump R. L. (2013). *Clostridium difficile* infection in older adults. *Aging health*, 9(4), 403–414.

- Kazanowski, M., Smolarek, S., Kinnarney, F., & Grzebieniak, Z. (2014). *Clostridium difficile*: epidemiology, diagnostic and therapeutic possibilities—a systematic review. *Techniques in coloproctology*, 18(3), 223-232.
- Kirkwood, Z. I., Millar, B. C., Downey, D. G., & Moore, J. E. (2018). Antimicrobial effect of dimethyl sulfoxide and N, N-Dimethylformamide on Mycobacterium abscessus: Implications for antimicrobial susceptibility testing. *International journal of mycobacteriology*, 7(2), 134.
- Kuhn, R., Böllmann, J., Krahl, K., Bryant, I. M., & Martienssen, M. (2018). Data on DNA gel sample load, gel electrophoresis, PCR and cost analysis. *Data in brief*, 16, 732-751.
- Lamont, J. T., Kelly, C. P., & Bakken, J. S. (2018). *Clostridioides* (formerly *Clostridium*) *difficile* infection in adults: *Clinical manifestations and diagnosis*.
- Leigue, L., Montiani-Ferreira, F., & Moore, B. A. (2016). Antimicrobial susceptibility and minimal inhibitory concentration of *Pseudomonas aeruginosa* isolated from septic ocular surface disease in different animal species. *Open veterinary journal*, 6(3), 215–222.
- Li, J. F., Huang, R. Z., Yao, G. Y., Ye, M. Y., Wang, H. S., Pan, Y. M., & Xiao, J. T. (2014). Synthesis and biological evaluation of novel aniline-derived asiatic acid derivatives as potential anticancer agents. *European journal of medicinal chemistry*, 86, 175-188.
- Lv, J., Sharma, A., Zhang, T., Wu, Y., & Ding, X. (2018). Pharmacological review on Asiatic acid and its derivatives: A potential compound. *SLAS TECHNOLOGY: Translating Life Sciences Innovation*, 23(2), 111-127.
- Mada, P. K., Alam, M. U. (2019). *Clostridium difficile*. *Treasure Island (FL): StatPearls Publishing*
- Maia, M. R., Marques, S., Cabrita, A. R., Wallace, R. J., Thompson, G., Fonseca, A. J., & Oliveira, H. M. (2016). Simple and Versatile Turbidimetric Monitoring of Bacterial Growth in Liquid Cultures Using a Customized 3D Printed Culture Tube Holder and a Miniaturized Spectrophotometer: Application to Facultative and Strictly Anaerobic Bacteria. *Frontiers in microbiology*, 7, 1381.
- Meeran, M. F. N., Goyal, S. N., Suchal, K., Sharma, C., Patil, C. R., & Ojha, S. K. (2018). Pharmacological properties, molecular mechanisms, and pharmaceutical development of asiatic acid: a pentacyclic triterpenoid of therapeutic promise. *Frontiers in pharmacology*, 9.
- Merrigan, M., Venugopal, A., Mallozzi, M., Roxas, B., Viswanathan, V. K., Johnson, S., ... & Vedantam, G. (2010). Human hypervirulent *Clostridium difficile* strains exhibit increased sporulation as well as robust toxin production. *Journal of bacteriology*, 192(19), 4904-4911.
- Mullany, P., & Roberts, A. (2010). *Clostridium difficile*. *New York: Humana Press*.
- National Center for Biotechnology Information. PubChem Database. Asiatic acid, CID=119034.
- National Committee for Clinical Laboratory Standards. 1998. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. *National Committee for Clinical Laboratory Standards, Wayne, Pa*.
- Ngamskulrungraj, P., Sanmee, S., Pusathit, P., Piewngam, P., Elliott, B., Riley, T. V., & Kiratisin, P. (2015). Molecular epidemiology of *Clostridium difficile* infection in a large teaching hospital in Thailand. *PloS one*, 10(5), e0127026.

- Patil, R., & Blankenship, L. (2013). Proton Pump Inhibitors and *Clostridium difficile* Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem?. *Gastroenterology research*, 6(5), 171–173.
- Pickard, J. M., Zeng, M. Y., Caruso, R., & Núñez, G. (2017). Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. *Immunological reviews*, 279(1), 70–89.
- Pittayanon, R., Treeprasertsuk, S., Phaosawasdi, K., Kitsahawong, B., Thepsuthammarat, K., & Kullavanijaya, P. (2015). The burden of *Clostridium difficile* infection in Thais: nationwide survey. *Asian Biomedicine*, 9(6), 783-788.
- Peng, Z., Jin, D., Kim, H. B., Stratton, C. W., Wu, B., Tang, Y. W., & Sun, X. (2017). Update on antimicrobial resistance in *Clostridium difficile*: resistance mechanisms and antimicrobial susceptibility testing. *Journal of clinical microbiology*, 55(7), 1998-2008.
- Rajeev, L. (2016). Antibiotic discovery. *Mat Meth*, 8, 2671.
- Rees, W. D., & Steiner, T. S. (2018). Adaptive immune response to *Clostridium difficile* infection: a perspective for prevention and therapy. *European Journal of Immunology*, 48(3), 398-406.
- Rineh, A., Kelso, M. J., Vatansever, F., Tegos, G. P., & Hamblin, M. R. (2014). *Clostridium difficile* infection: molecular pathogenesis and novel therapeutics. *Expert review of anti-infective therapy*, 12(1), 131–150.
- Salazar, C. L., Reyes, C., Cienfuegos-Gallet, A. V., Best, E., Atehortua, S., Sierra, P., ... Gonzalez, A. (2018). Subtyping of *Clostridium difficile* PCR ribotypes 591, 106 and 002, the dominant strain types circulating in Medellin, Colombia. *PloS one*, 13(4), e0195694.
- Sarker, M. R., & Paredes-Sabja, D. (2012). Molecular basis of early stages of *Clostridium difficile* infection: germination and colonization. *Future Microbiology*, 7(8), 933–943. doi:10.2217/fmb.12.64
- Schaeffler, H., & Breitrueck, A. (2018). *Clostridium difficile*—From colonization to infection. *Frontiers in microbiology*, 9, 646.
- Seekatz, A. M., & Young, V. B. (2014). *Clostridium difficile* and the microbiota. *The Journal of clinical investigation*, 124(10), 4182–4189.
- Spigaglia, P., Mastrantonio, P., & Barbanti, F. (2018). Antibiotic Resistances of *Clostridium difficile*. *Updates on Clostridium difficile in Europe*, 137–159.
- Stabler, R. A., He, M., Dawson, L., Martin, M., Valiente, E., Corton, C., Lawley, T. D., Sebahia, M., Quail, M. A., Rose, G., Gerding, D. N., Gibert, M., Popoff, M. R., Parkhill, J., Dougan, G., & Wren, B. W. (2009). Comparative genome and phenotypic analysis of *Clostridium difficile* O27 strains provides insight into the evolution of a hypervirulent bacterium. *Genome biology*, 10(9), R102.
- Stabler, R. A., Valiente, E., Dawson, L. F., He, M., Parkhill, J., & Wren, B. W. (2010). In-depth genetic analysis of *Clostridium difficile* PCR-ribotype O27 strains reveals high genome fluidity including point mutations and inversions. *Gut microbes*, 1(4), 269–276.

- Stubbs, S. L., Brazier, J. S., O'Neill, G. L., & Duerden, B. I. (1999). PCR targeted to the 16S-23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. *Journal of clinical microbiology*, 37(2), 461–463.
- Theriot, C. M., & Young, V. B. (2015). Interactions between the gastrointestinal microbiome and *Clostridium difficile*. *Annual review of microbiology*, 69, 445-461.
- Tyrrell, K. L., Citron, D. M., Leoncio, E. S., Merriam, C. V., & Goldstein, E. J. (2013). Evaluation of cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate, and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme for recovery of *Clostridium difficile* isolates from fecal samples. *Journal of clinical microbiology*, 51(9), 3094–3096.
- Valiente, E., Dawson, L. F., Cairns, M. D., Stabler, R. A., & Wren, B. W. (2012). Emergence of new PCR ribotypes from the hypervirulent *Clostridium difficile* 027 lineage. *Journal of medical microbiology*, 61(Pt 1), 49–56.
- Viswanathan, V. K., Mallozzi, M., & Vedantam, G. (2010). *Clostridium difficile* infection: An overview of the disease and its pathogenesis, epidemiology and interventions. *Gut microbes*, 1(4), 234-242.
- Wieczorkiewicz, J. T., Lopansri, B. K., Cheknis, A., Osmolski, J. R., Hecht, D. W., Gerding, D. N., & Johnson, S. (2016). Fluoroquinolone and macrolide exposure predict *Clostridium difficile* infection with the highly fluoroquinolone-and macrolide-resistant epidemic *C. difficile* strain BI/NAP1/027. *Antimicrobial agents and chemotherapy*, 60(1), 418-423.
- Weinstein, M. P., & Lewis, J. S. (2020). The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes. *Journal of clinical microbiology*, 58(3).
- Wojnicz, D., Tichaczek-Goska, D., Korzekwa, K., Kicia, M., and Hendrich, A. (2017). Anti-enterococcal activities of pentacyclic triterpenes. *Adv. Clin. Exp. Med.* 26, 483–490.
- Wong, K., Hag Ali, D. M., & Boey, P. (2012). Chemical constituents and antibacterial activity of *Melastoma malabathricum* L. *Natural Product Research*, 26(7), 609-618.
- Yuan, Y., Zhang, H., Sun, F., Sun, S., Zhu, Z., and Chai, Y. (2015). Biopharmaceutical and pharmacokinetic characterization of asiatic acid in *C. asiatica* as determined by a sensitive and robust HPLC-MS method. *J. Ethnopharmacol.* 163, 31–38.
- Zeng, W., Shen, J., Bo, T., Peng, L., Xu, H., Nasser, M. I., Zhuang, Q., & Zhao, M. (2019). Cutting Edge: Probiotics and Fecal Microbiota Transplantation in Immunomodulation. *Journal of immunology research*, 2019, 1603758.